SCHEMBL6668985

SCHEMBL6668985

Cc1c(F)c(N2CCOCC2)c(C)c2c1c(=O)[nH]c(=O)n2C1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CHRM2 P08172 2/20 0.36
CHRM4 P08173 2/20 0.36
CHRM5 P08912 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
KCNH2 Q12809 2/20 0.36
TPH1 P17752 1/20 0.35
TPH2 Q8IWU9 1/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
PDE3B Q13370 2/20 0.35
PDE3A Q14432 2/20 0.35
HIF1A Q16665 2/20 0.33
RAB9A P51151 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6672115 0.89 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AKCNH2TPH1
SCHEMBL6646292 0.88 ALDH1A1 (0.35) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL6671831 0.88 MEN1 (0.35) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL6671122 0.87 CCNC (0.35) ALDH1A1KCNH2TPH1TPH2HPGD
SCHEMBL6670133 0.83 PIM3 (0.38) ALDH1A1CHRM2CHRM1KCNH2
SCHEMBL6673140 0.81 KCNH2 (0.35) KCNH2
SCHEMBL6671662 0.81 ALDH1A1 (0.33) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL7097575 0.80 KCNH2 (0.35) KCNH2
SCHEMBL6668094 0.79 KCNH2 (0.34) KCNH2
SCHEMBL6670930 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401830-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2004-03-31 EP claimed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 US claimed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 WO claimed
EP-1401830-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS Warner-Lambert Company LLC (US) 2004-03-31 EP disclosed
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance WARNER-LAMBERT COMPANY 2003-06-19 US disclosed
WO-2002102793-A2 QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114666-A1 Having quinazolindione core structure; non-antibiotic resistance ABCC1, RPS6KA1, SIGMAR1 ALDH1A1 781/4885MEN1 1257/4885KMT2A 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.